Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome

Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) affects approximately 1% of the general population. It is a chronic, disabling, multi-system disease for which there is no effective treatment. This is probably related to the limited knowledge about its origin. Here, we summarized the c...

ver descrição completa

Detalhes bibliográficos
Autores: Ruiz-Pablos, M. (Manuel)|||/items/7f4426eb-674e-4fb6-8e35-786278eb9da9, Paiva, B. (Bruno)|||/items/b2c3efc5-27e1-4425-b452-efba1522c1d5, Garcia, N. (Nicolás)|||/items/f28987d6-9dc4-4d34-9f80-436b9bddb930, Zabaleta-Apiroz, A. (Aintzane)|||/items/b22de5a6-cfd3-41a9-8d6a-004c620cc6a5, Montero-Mateo, R. (Rosario)|||/items/36598916-c793-40e3-8821-47af719410ee
Formato: artículo
Fecha de publicación:2021
País:España
Recursos:Universidad de Navarra
Repositorio:Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:inglés
OAI Identifier:oai:dadun.unav.edu:10171/115945
Acesso em linha:https://hdl.handle.net/10171/115945
Access Level:acceso abierto
Palavra-chave:CD4+ CTL
EBV EBNA-1
HLA-II alleles
Autoimmunity
Cancer
Chronic fatigue syndrome
Immunotherapy
Myalgic encephalomyelitis
id ES_8dc35ea3abbf71b5b866709bc85674b0
oai_identifier_str oai:dadun.unav.edu:10171/115945
network_acronym_str ES
network_name_str España
repository_id_str
spelling Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndromeRuiz-Pablos, M. (Manuel)|||/items/7f4426eb-674e-4fb6-8e35-786278eb9da9Paiva, B. (Bruno)|||/items/b2c3efc5-27e1-4425-b452-efba1522c1d5Garcia, N. (Nicolás)|||/items/f28987d6-9dc4-4d34-9f80-436b9bddb930Zabaleta-Apiroz, A. (Aintzane)|||/items/b22de5a6-cfd3-41a9-8d6a-004c620cc6a5Montero-Mateo, R. (Rosario)|||/items/36598916-c793-40e3-8821-47af719410eeCD4+ CTLEBV EBNA-1HLA-II allelesAutoimmunityCancerChronic fatigue syndromeImmunotherapyMyalgic encephalomyelitisMyalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) affects approximately 1% of the general population. It is a chronic, disabling, multi-system disease for which there is no effective treatment. This is probably related to the limited knowledge about its origin. Here, we summarized the current knowledge about the pathogenesis of ME/CFS and revisit the immunopathobiology of Epstein-Barr virus (EBV) infection. Given the similarities between EBV-associated autoimmune diseases and cancer in terms of poor T cell surveillance of cells with EBV latency, expanded EBV-infected cells in peripheral blood and increased antibodies against EBV, we hypothesize that there could be a common etiology generated by cells with EBV latency that escape immune surveillance. Albeit inconclusive, multiple studies in patients with ME/CFS have suggested an altered cellular immunity and augmented Th2 response that could result from mechanisms of evasion to some pathogens such as EBV, which has been identified as a risk factor in a subset of ME/CFS patients. Namely, cells with latency may evade the immune system in individuals with genetic predisposition to develop ME/CFS and in consequence, there could be poor CD4 T cell immunity to mitogens and other specific antigens, as it has been described in some individuals. Ultimately, we hypothesize that within ME/CFS there is a subgroup of patients with DRB1 and DQB1 alleles that could confer greater susceptibility to EBV, where immune evasion mechanisms generated by cells with latency induce immunodeficiency. Accordingly, we propose new endeavors to investigate if anti-EBV therapies could be effective in selected ME/CFS patients.Frontiers Media S.A.Dadun. Depósito Académico Digital Universidad de Navarra20212021-01-0120212021-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/115945reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/1159452026-06-21T12:47:57Z
dc.title.none.fl_str_mv Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
title Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
spellingShingle Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
Ruiz-Pablos, M. (Manuel)|||/items/7f4426eb-674e-4fb6-8e35-786278eb9da9
CD4+ CTL
EBV EBNA-1
HLA-II alleles
Autoimmunity
Cancer
Chronic fatigue syndrome
Immunotherapy
Myalgic encephalomyelitis
title_short Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
title_full Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
title_fullStr Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
title_full_unstemmed Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
title_sort Epstein-Barr virus and the origin of myalgic encephalomyelitis or chronic fatigue syndrome
dc.creator.none.fl_str_mv Ruiz-Pablos, M. (Manuel)|||/items/7f4426eb-674e-4fb6-8e35-786278eb9da9
Paiva, B. (Bruno)|||/items/b2c3efc5-27e1-4425-b452-efba1522c1d5
Garcia, N. (Nicolás)|||/items/f28987d6-9dc4-4d34-9f80-436b9bddb930
Zabaleta-Apiroz, A. (Aintzane)|||/items/b22de5a6-cfd3-41a9-8d6a-004c620cc6a5
Montero-Mateo, R. (Rosario)|||/items/36598916-c793-40e3-8821-47af719410ee
author Ruiz-Pablos, M. (Manuel)|||/items/7f4426eb-674e-4fb6-8e35-786278eb9da9
author_facet Ruiz-Pablos, M. (Manuel)|||/items/7f4426eb-674e-4fb6-8e35-786278eb9da9
Paiva, B. (Bruno)|||/items/b2c3efc5-27e1-4425-b452-efba1522c1d5
Garcia, N. (Nicolás)|||/items/f28987d6-9dc4-4d34-9f80-436b9bddb930
Zabaleta-Apiroz, A. (Aintzane)|||/items/b22de5a6-cfd3-41a9-8d6a-004c620cc6a5
Montero-Mateo, R. (Rosario)|||/items/36598916-c793-40e3-8821-47af719410ee
author_role author
author2 Paiva, B. (Bruno)|||/items/b2c3efc5-27e1-4425-b452-efba1522c1d5
Garcia, N. (Nicolás)|||/items/f28987d6-9dc4-4d34-9f80-436b9bddb930
Zabaleta-Apiroz, A. (Aintzane)|||/items/b22de5a6-cfd3-41a9-8d6a-004c620cc6a5
Montero-Mateo, R. (Rosario)|||/items/36598916-c793-40e3-8821-47af719410ee
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv CD4+ CTL
EBV EBNA-1
HLA-II alleles
Autoimmunity
Cancer
Chronic fatigue syndrome
Immunotherapy
Myalgic encephalomyelitis
topic CD4+ CTL
EBV EBNA-1
HLA-II alleles
Autoimmunity
Cancer
Chronic fatigue syndrome
Immunotherapy
Myalgic encephalomyelitis
description Myalgic encephalomyelitis or chronic fatigue syndrome (ME/CFS) affects approximately 1% of the general population. It is a chronic, disabling, multi-system disease for which there is no effective treatment. This is probably related to the limited knowledge about its origin. Here, we summarized the current knowledge about the pathogenesis of ME/CFS and revisit the immunopathobiology of Epstein-Barr virus (EBV) infection. Given the similarities between EBV-associated autoimmune diseases and cancer in terms of poor T cell surveillance of cells with EBV latency, expanded EBV-infected cells in peripheral blood and increased antibodies against EBV, we hypothesize that there could be a common etiology generated by cells with EBV latency that escape immune surveillance. Albeit inconclusive, multiple studies in patients with ME/CFS have suggested an altered cellular immunity and augmented Th2 response that could result from mechanisms of evasion to some pathogens such as EBV, which has been identified as a risk factor in a subset of ME/CFS patients. Namely, cells with latency may evade the immune system in individuals with genetic predisposition to develop ME/CFS and in consequence, there could be poor CD4 T cell immunity to mitogens and other specific antigens, as it has been described in some individuals. Ultimately, we hypothesize that within ME/CFS there is a subgroup of patients with DRB1 and DQB1 alleles that could confer greater susceptibility to EBV, where immune evasion mechanisms generated by cells with latency induce immunodeficiency. Accordingly, we propose new endeavors to investigate if anti-EBV therapies could be effective in selected ME/CFS patients.
publishDate 2021
dc.date.none.fl_str_mv 2021
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/10171/115945
url https://hdl.handle.net/10171/115945
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Frontiers Media S.A.
publisher.none.fl_str_mv Frontiers Media S.A.
dc.source.none.fl_str_mv reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra
instname:Universidad de Navarra
instname_str Universidad de Navarra
reponame_str Dadun. Depósito Académico Digital de la Universidad de Navarra
collection Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869413072799531008
score 15.811543

Registos relacionados